Home / Going-concern warnings / Phio Pharmaceuticals Corp.
Filed 2026-03-05 路 Form 10-K 路 Accession 0001437749-26-007078 nano
Price before filing: $1.15 (2026-03-04 close, split/dividend-adjusted)
Market cap at flag: $13.6M (2026-03-05) 路 Latest: $10.1M (2026-10-16)
| Window | PHIO | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | +9.6% | -3.6% | +13.1% | 2026-04-06 |
| 90 days | -3.5% | +10.4% | -13.9% | 2026-06-03 |
| 180 days | -4.3% | +11.8% | -16.1% | 2026-09-01 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
"As discussed in Note 1 to the consolidated financial statements, the Company has suffered recurring losses from operations and negative cash flows from operations that raise substantial doubt about its ability to continue as a going concern."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Source: independent auditor report in Form 10-K (period 2025-12-31)
Why this score: in auditor's report
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Newsletter delivered by beehiiv. See our privacy policy.